Experimental Vaccines for Prevention of Marburg Hemorrhagic Fever and Animal Models for Studying Pathogenesis
https://doi.org/10.21055/0370-1069-2018-3-8-15
Abstract
Marburg fever is an acute natural-focal disease characterized by severe course, hemorrhagic syndrome, high level of contagiousness and lethality. The causative agent of the disease is the RNA-containing virus belonging to the family of filoviruses (Filoviridae). The main problem faced by doctors and scientists involved in the fight against Marburg fever is the lack of vaccines and preventive drugs against this disease. The development of effective vaccines against filovirus infection is relevant for protecting the population living in natural foci and medical personnel during epidemic outbreaks, as well as for ensuring safe research work in BSL-4 laboratories. In this regard, this review considers biomodels suitable for studying the pathogenesis of filovirus infections, preclinical studies of specific activity and harmlessness of prototype Marburg virus vaccines and variants of these vaccines.
About the Authors
N. V. Volkova
State Scientific Centre of Virology and Biotechnology “Vector”, Kol’tsovo
Russian Federation
Russian Federation
Kol’tsovo, Novosibirsk Region, 630559
E. I. Kazachinskaya
State Scientific Centre of Virology and Biotechnology “Vector”, Kol’tsovo
Russian Federation
Kol’tsovo, Novosibirsk Region, 630559
Russian Federation
Kol’tsovo, Novosibirsk Region, 630559
D. N. Shcherbakov
State Scientific Centre of Virology and Biotechnology “Vector”, Kol’tsovo
Russian Federation
Kol’tsovo, Novosibirsk Region, 630559
Russian Federation
Kol’tsovo, Novosibirsk Region, 630559
References
1. Siegert R., Shu H.L., Slenczka W., Peters D, Müller G. On the etiology of an unknown human infection originating from monkeys. Dtsch. Med. Wochenschr.1967; 92(51):2341–3. DOI: 10.1055/s-0028-1106144.
2. Negredo A., Palacios G., Vazquez-Moron S., Gonzalez F., Dopazo H., Molero F., Juste J., Quetglas J., Savji N., dela CruzMartinez M., Herrera J.E., Pizarro M., Hutchison S.K., Echevarria J.E., Lipkin W.I., Tenorio A. Discovery of an EbolavirusLike Filovirus in Europe. PLoS Pathog. 2011; 7(10):e1002304. DOI: 10.1371/journal.ppat.1002304.
3. Beer B., Kurth R., Bukreyev A. Characteristics of Filoviridae: Marburg and Ebola viruses. Naturwissenschaften. 1999; 86(1):8–17. DOI: 10.1007/s001140050562.
4. Nikiforov V.V., Turovskoi Yu.I., Kalinin P.P. [A case of laboratory infection with Marburg fever]. Mikrobiologiya. 1994; 63(3):104–10. (In Russ.)
5. Towner J.S., Khristova M.L., Sealy T.K., Vincent M. J., Erickson B. R., Bawiec D.A., Hartman A. L., Comer J. A., Zaki S.R Ströher U., Gomes da Silva F, del Castillo F., Rollin P. E., Ksiazek T. G., Nichol1 S. T. Marburgvirus genomics and association with a large hemorrhagic fever outbreak in Angola. J. Virol. 2006; 80(13):6497–6. DOI: 10.1128/JVI.00069-06.
6. Mire C.E., Geisbert J.B., Agans K.N., Satterfield B.A., Versteeg K.M., Fritz E.A., Feldmann H., Hensley L.E., Geisbert T.W. Durability of a vesicular stomatitis virus based Marburg virus vaccine in nonhuman primates. PLoS One. 2014; 9(4):e94355. DOI: 10.1371/journal.pone.0094355.
7. Qiu X., Wong G., Audet J., Cutts T., Niu Y., Booth S., Kobinger G.P. Establishment and characterization of a lethal mouse model for the Angola strain of Marburg virus. J. Virol. 2014; 88(21):12703–14. DOI: 10.1128/JVI.01643-14.
8. Sridhar S. Clinical development of Ebola vaccines. Ther. Adv. Vaccines. 2015; 3(5–6):125–38. DOI: 10.1177/2051013615611017.
9. Baron R.C., McCormick J.B., Zubeir O.A. Ebola virus disease in southern Sudan. Hospital dissemination and intrafamilial spread. Bull World Health Organ. 1983; 61(6):997–1003. PubMed PMID: 6370486.
10. Pokhodaev V.A., Gonchar N.I., Pshenichnov V.A. [Experimental study of Marburg virus contact-type transmission]. Voprosy Virusologii. 1991; (6):506–8. (In Russ.)
11. Johnson E., Jaax N., White J. Lethal experimental infection of rhesus monkeys by aerosolized Ebola virus. Int. J. Exp. Pathol. 1995; 76(4):227–36. PMCID: PMC1997182.
12. Kobinger G.P., Leung A., Neufeld J., Richardson J.S., Falzarano D., Smith G., Tierney K., Patel A., Weingartl H.M. Replication, pathogenicity, shedding, and transmission of Zaire ebolavirus in pigs. J. Infect. Dis.2011; 204(2):200–8. DOI: 10.1093/infdis/jir077.
13. Weingartl H.M., Embury-Hyatt C., Nfon C., Leung A., Smith G., Kobinger G. Transmission of Ebola virus from pigs to nonhuman primates. Sci. Rep. 2012; 2:811. DOI: 10.1038/srep00811.
14. Schuh A.J., Amman B.R., Jones M.E.B., Sealy T.K., Uebelhoer L.S., Spengler J.R., Martin B.E., Coleman-McCray J.A.D., Nichol S.T., Towner J.S. Modelling filovirus maintenance in nature by experimental transmission of Marburg virus between Egyptian rousette bats. Nat. Commun.2017; 8:14446. DOI: 10.1038/ncomms14446.
15. Telesmanich N.R., Mikashinovich Z.I., Lomakovsky N.S., Loseva T.D., Chaika S.O. [Biochemistry of Ebola virus and molecular aspects of biological protection]. Zhurnal Fundamental’noi i Molekulyarnoi Meditsiny i Biologii.2015; (3):28–34. (In Russ.)
16. Matassov D., Mire C.E., Latham T., Geisbert J.B., Xu R., Ota-Setlik A., Agans K.N., Kobs D.J., Wendling M.Q.S., Burnaugh A., Rudge T.L. Jr., Sabourin C.L., Egan M.A., Clarke D.K., Geisbert T.W., Eldridge J.H. Single dose trivalent vesiculovax vaccine protects macaques from lethal Ebolavirus and Marburgvirus challenge. J. Virol. 2017; 92(3):e01190–17. DOI: 10.1128/JVI.01190-17.
17. Paweska J. T., Storm N., Grobbelaar A.A., Markotter W., Kemp A., van Vuren P.J. Experimental inoculation of Egyptian fruit bats (Rousettus aegyptiacus) with Ebola virus. Viruses. 2016; 8(2):E29. DOI: 10.3390/v8020029.
18. Han Z., Bart S.M., Ruthel G., VandeBurgt N.H., Haines K.M., Volk S.W., Vite C.H., Freedman B.D., Bates P., Harty R.N. Ebola virus mediated infectivity is restricted in canine and feline cells. Vet. Microbiol. 2016; 182:102–7. DOI: 10.1016/j.vetmic.2015.11.011.
19. WHO Report. Ebola Reston virus detected pigs in the Philippines. 2009; 14(4):19105. PubMed PMID: 19215709.
20. Krasnyansky V.P., Mikhailov V.V., Borisevich I.V., Gradoboev V.N., Evseev A.A., Pshenichnov V.A. [Production of hyper-immune equine serum against Ebola virus]. Voprosy Virusologii. 1994; 39(2):91–2. (In Russ.)
21. Chepurnov A.A., Merzlikin N.V., Chepurnova T.S., Vorob’eva M.S. [Production of rabbit anti-sera to Ebola virus]. Voprosy Virusologii. 1994; 39(6):286–8. (In Russ.)
22. Chepurnov A.A., Kudoyarova-Zubovichine N.M., Dedkova L.M. [Development of the methods for specific immunoglobulin production for emergency prophylaxis of Ebola fever and investigation of the immunoglobulin properties]. Bulletin of the Russian Academy of Medical Sciences (Vestnik Rossiiskoi Akademii Meditsinskikh Nauk).1998; 68(4):24–9. (In Russ.)
23. Nakayama E., Saijo M. Animal models for Ebola and Marburg virus infections. Front. Microbiol. 2013; 4:267. DOI: 10.3389/fmicb.2013.00267.
24. Marzi A., Banadyga L., Haddock E., Thomas T., Shen K., Horne EJ., Scott D.P., Feldmann H., Ebihara H. A hamster model for Marburg virus infection accurately recapitulates Marburg hemorrhagic fever. Sci. Rep. 2016; 6:39214. DOI: 10.1038/srep39214.
25. Natesan M., Jensen S.M., Keasey S.L., Kamata T., Kuehne A.I., Stonier S.W., Lutwama J.J., Lobel L., Dye J.M., Ulrich R.G. Human survivors of disease outbreaks caused by Ebola or Marburg virus exhibit cross-reactive and long-lived antibody responses. Clin. Vaccine Immunol. 2016; 23(8):717–24. DOI: 10.1128/CVI.00107-16.
26. Hevey M., Negley D., VanderZanden L., Tammariello R.F., Geisbert J., Schmaljohn C., Smith J.F., Jahrling P.B., Schmaljohn A.L. Marburg virus vaccines: comparing classical and new approaches. Vaccine. 2001;20(3–4):586–93. PubMed PMID: 11672925.
27. Ignat’ev G.M., Agafonov A.P., Strel’tsova M.A., Kuz’min V.A. [Comparative study of certain immunological features in case of inoculation of guinea pigs with inactivated Marburg virus]. Voprosy Virusologii. 1991; 36(2):421–3. (In Russ.)
28. Ignat’ev G.M., Agafonov A.P., Streltsova M.A., Kashentseva E. A. Inactivated Marburg virus elicits a nonprotective immune response in Rhesus monkeys. J. Biotechnol. 1996; 44(1–3):111–18. DOI: 10.1016/0168-1656(95)00104-2.
29. Grant-Klein R.J., Altamura L.A., Badger C.V., Bounds C.E., VanDeusen N.M., Kwilas S.A., Vu H.A., Warfield K.L., Hooper J.W., Hannaman D., Dupuy L.C., Schmaljohn C.S. Codon-optimized filovirus DNA vaccines delivered by intramuscular electroporation protect cynomolgus macaques from lethal Ebola and Marburg virus challenges. Hum. Vaccin. Immunother.2015; 11(8):1991–2004. DOI: 10.1080/21645515.2015.1039757.
30. Riemenschneider J., Garrison A., Geisbert J., Jahrling P., Hevey M., Negley D., Schmaljohna A, Leea J, Harta M. K., Vanderzandena L, Custera D, Braya M, Ruffa A, Ivinsb B, Bassettb A, Rossic C, Schmaljohna C. Comparison of individual and combination DNA vaccines for B. anthracis, Ebola virus, Marburg virus and Venezuelan equine encephalitis virus. Vaccine. 2003; 21(25–26):4071–80. DOI: 10.1016/S0264-410X(03)00362-1.
31. Geisbert T. W., Bailey M., Geisbert J. B., Asiedu C., Roederer M., Grazia-Pau M., Custers J, Jahrling P, Goudsmit J, Koup R, Nancy J. Sullivan N.J. Vector choice determines immunogenicity and potency of genetic vaccines against Angola Marburg virus in nonhuman primates. J. Virol. 2010; 84(19):10386–94. DOI: 10.1128/JVI.00594-10.
32. Sarwar U.N., Costner P., Enama M.E., Berkowitz N., Hu Z., Hendel C.S., Sitar S., Plummer S., Mulangu S., Bailer R.T., Koup R.A., Mascola J.R., Nabel G.J., Sullivan N.J., Graham B.S., Ledgerwood J.E; VRC 206 Study Team. Safety and immunogenicity of DNA vaccines encoding Ebolavirus and Marburgvirus wildtype glycoproteins in a phase I clinical trial. J. Infect. Dis. 2015; 211(4):549–57. DOI: 10.1093/infdis/jiu511.
33. Kibuuka H., Berkowitz N.M., Millard M., Enama M.E., Tindikahwa A., Sekiziyivu A.B., Costner P., Sitar S., Glover D., Hu Z., Joshi G., Stanley D., Kunchai M., Eller L.A., Bailer R.T., Koup R.A., Nabel G.J., Mascola J.R., Sullivan N.J., Graham B.S., Roederer M., Michael N.L., Robb M.L., Ledgerwood J.E; RV 247 StudyTeam. Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial. Lancet.2015; 385(9977):1545–54. DOI: 10.1016/S0140-6736(14)62385-0.
34. Milligan I.D.,Gibani M.M., Sewell R., Clutterbuck E.A., Campbell D., Plested E., Nuthall E., Voysey M., Silva-Reyes L., Mc Elrath M.J., DeRosa S.C., Frahm N., Cohen K.W., Shukarev G., Orzabal N., van Duijnhoven W., Truyers C., Bachmayer N., Splinter D., Samy N., Pau M.G., Schuitemaker H., Luhn K., Callendret B., Van Hoof J., Douoguih M., Ewer K., Angus B., Pollard A.J., Snape M.D. Safety and immunogenicity of novel adenovirus type 26- and modified vaccinia Ankara-vectored Ebola vaccines: a randomized clinical trial. JAMA. 2016; 315(15):1610–23. DOI: 10.1001/jama.2016.4218.
35. Dolzhikova I.V., Tokarskaya E.A., Dzharullaeva A.S., Tukhvatulin A.I., Shcheblyakov D.V., Voronina O.L., Syromyatnikova S.I., Borisevich S.V., Pantyukhov V.B., Babira V.F., Kolobukhina L.V., Naroditsky B.S., Logunov D.Y., Gintsburg A. L. Virus-vectored Ebola vaccines. Acta Naturae.2017; 9 (3):4–12.
36. Li J.X., Hou L.H., Meng F.Y., Wu S.P., Hu Y.M., Liang Q., Chu K., Zhang Z., Xu J.J., Tang R., Wang W.J., Liu P, Hu J.L., Luo L., Jiang R., Zhu F.C., Chen W. Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Glob. Health. 2017; 5(3):e324–e334. DOI: 10.1016/S2214-109X (16)30367-9.
37. Coller B.G., Blue J., Das R., Dubey S., Finelli L., Gupta S., Helmond F., Grant-Klein R.J., Liu K., Simon J., Troth S., Van Rheenen S., Waterbury J., Wivel A., Wolf J., Heppner D.G., Kemp T., Nichols R., Monath T.P. Clinical development of a recombinant Ebola vaccine in the midst of an unprecedented epidemic. Vaccine. 2017; 35(35 Pt A):4465–4469. DOI: 10.1016/j.vaccine.2017.05.097.
38. Geisbert T.W., Geisbert J.B., Leung A., Daddario-Dicaprio K.M., Hensley L.E., Grolla A., Feldmann H. Single-injection vaccine protects nonhuman primates against infection with Marburg virus and three species of Ebola virus. J. Virol. 2009; 83(14):7296–304. DOI: 10.1128/JVI.00561-09.
39. Noda T., Sagara H., Suzuki E., Takada A, Kida H., Kawaoka Y. Ebola virus VP40 drives the formation of virus-like filamentous particles along with GP. J. Virol. 2002; 76(10):4855–65. PubMed PMID: 11967302.
40. Licata J., Johnson R.F., Han Z. Harty R.N. Contribution of Ebola virus glycoprotein, nucleoprotein, and VP24 to budding of VP40 virus-like particles. J. Virol. 2004; 78(14):7344–51. DOI: 10.1128/JVI.78.14.7344-7351.2004.
41. Swenson D.L., Warfield K.L., Larsen T., Alves D.A., Coberley S.S., Bavari S. Monovalent virus-like particle vaccine protects guinea pigs and nonhuman primates against infection with multiple Marburg viruses. Expert. Rev. Vaccines. 2008; 7(4):417–29. DOI: 10.1586/14760584.7.4.417.
42. Dye J.M.,Warfield K.L., Wells J.B., Unfer R.C., Shulenin S., Vu H., Nichols D.K., Aman M.J., Bavari S. Virus-Like Particle Vaccination Protects Nonhuman Primates from Lethal Aerosol Exposure with Marburgvirus (VLP Vaccination Protects Macaques against Aerosol Challenges). Viruses. 2016; 8(4):94. DOI: 10.3390/v8040094
Review
For citations:
Volkova N.V., Kazachinskaya E.I., Shcherbakov D.N. Experimental Vaccines for Prevention of Marburg Hemorrhagic Fever and Animal Models for Studying Pathogenesis. Problems of Particularly Dangerous Infections. 2018;(3):8-15. (In Russ.) https://doi.org/10.21055/0370-1069-2018-3-8-15
Views:
1628
Email this article 